SMARCD3

Across TCGA pan-cancer cohorts, SMARCD3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SMARCD3 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher SMARCD3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SMARCD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

UCEC, PDAC, and LSCC are the cancer types where SMARCD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Tertile	II,III,IV	0.434	1.000	.006	36	view →
PDAC	OS	Quartile	II,III,IV	0.915	0.643	.004	34	view →
LSCC	DFS	Tertile	II,III,IV	0.633	0.902	.011	11	view →
LUAD	DFS	Tertile	All	0.533	1.000	.010	4	view →
GBM	DFS	Median	All	0.238	0.490	.007	3	view →
CCRCC	OS	Quartile	II,III,IV	0.610	1.000	.028	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SMARCD3–UCEC (OS)

Open the UCEC breakdown →